论文部分内容阅读
目的观察参麦注射液治疗糖尿病合并慢性心力衰竭的临床效果,并初步探讨其作用机理。方法选择2011年1月—2012年12月收治的糖尿病合并慢性心力衰竭患者60例作为研究对象,随机分为对照组和治疗组各30例。对照组给予单纯西药常规治疗,治疗组在对照组的基础上给予参麦注射液治疗,两组均治疗14 d。记录并比较两组治疗前后临床症状改善情况及血液流变学结果。计量资料采用t检验,计数资料采用χ~2检验,P<0.05为差异有统计学意义。结果治疗后,治疗组患者心悸气急、乏力、水肿改善有效率分别为96.55%、92.86%、92.86%,均高于对照组的75.00%、65.38%、61.11%,差异均有统计学意义(均P<0.05)。治疗后,治疗组高切全血黏度、低切全血黏度、血浆纤维蛋白原、红细胞沉降率分别为(4.16±0.39)、(8.41±0.72)mPa·s、(2.50±0.31)g/L、(9.50±3.31)mm/h,与对照组的(4.94±0.56)、(9.42±0.64)mPa·s、(3.46±0.21)g/L、(13.46±5.46)mm/h比较差异均有统计学意义(均P<0.05)。结论参麦注射液有助于改善心脏功能,减轻患者心力衰竭临床症状,提高治疗有效率,可能与改善血液流变学有关。
Objective To observe the clinical effect of Shenmai injection in the treatment of diabetes mellitus combined with chronic heart failure and to explore its mechanism. Methods Sixty patients with diabetes mellitus and chronic heart failure who were admitted to our hospital from January 2011 to December 2012 were selected and randomly divided into control group and treatment group. The control group was treated with conventional western medicine only. The treatment group was given Shenmai injection on the basis of the control group, both of which were treated for 14 days. Record and compare the two groups before and after treatment to improve the clinical symptoms and hemorheology results. Measurement data using t test, count data using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results After treatment, the improvement rate of palpitations, palpitation, fatigue and edema were 96.55%, 92.86% and 92.86% respectively in the treatment group, which were significantly higher than those in the control group (75.00%, 65.38% and 61.11%, both P <0.05). After treatment, the values of whole blood viscosity, low cut whole blood viscosity, plasma fibrinogen and erythrocyte sedimentation rate were (4.16 ± 0.39), (8.41 ± 0.72) mPa · s and (2.50 ± 0.31) g / L , (9.50 ± 3.31) mm / h, respectively, compared with the control group (4.94 ± 0.56), (9.42 ± 0.64) mPa · s, (3.46 ± 0.21) g / L and (13.46 ± 5.46) mm / Statistical significance (all P <0.05). Conclusion Shenmai injection can improve cardiac function, alleviate the clinical symptoms of heart failure and improve the therapeutic efficiency, which may be related to the improvement of hemorheology.